Intelligence / Healthtech / PMA Approvals / Lemaitre Vascular, INC.
Approvalsdevice change approved (PMA)4 Sept 2026
Lemaitre Vascular, INC.
4 Sept 2026: Device change approved (PMA) · Artegraft Collagen Vascular Graft. Recorded in the openFDA device PMA data.
- Decided
- 4 Sept 2026
- Device
- Artegraft Collagen Vascular Graft
- Specialty
- Cardiovascular
- Type
- Supplement (Special (Immediate Track))
- Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Reference
- N16837 S039
- Location
- Burlington, MA
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Lemaitre Vascular, INC.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Lemaitre Vascular, INC. in our registers.
More in Cardiovascular
PMA Approvals
6 NovAbbott Vascular (Idef Technologies INC)device change approved (PMA) · Supera Peripheral Stent SystemApprovals6 NovMedalliance, LLCdevice change approved (PMA) · SELUTION SLR 014 PTCA Drug-Eluting BalloonApprovals5 NovAbbott Medicaldevice change approved (PMA) · UltiSynq Defibrillation lead; SurGrip Suture Sleeve AccessoryApprovals4 NovContego Medical, INC.device change approved (PMA) · Neuroguard IEP® 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic ProtectionApprovals4 NovMedtronic Cardiac Rhythm Disease Managementdevice change approved (PMA) · Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome MApprovals4 NovMedtronic Cardiac Rhythm Disease Managementdevice change approved (PMA) · Cobalt MRI ICD (DDPB3D1, DDPB3D4, DVPB3D1, DVPB3D4); Cobalt XT MRI ICD (DDPA2D1, DDPA2D4, DVPA2D1, DVPA2D4); Crome MRI IApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.